Pet health expansion Avrio Pharmacy recently launched GS-441524 for feline FIP with a relapse guarantee, indicating a strategic expansion into high-demand veterinary pharmaceuticals and pet owner-focused products that present cross-sell opportunities to current clients and veterinary networks.

On-site compounding The presence of an in-house compounding lab enables Customized prescriptions and differentiated services which can be monetized through targeted B2B partnerships with clinics, veterinarians, and specialty care providers seeking personalized medication solutions.

Online accessibility With online prescription refills and medication information, there is potential to upsell digital health services, subscription models, and telepharmacy offerings to both human and pet owners, leveraging existing tech stack.

Mid-market focus Revenue in the $25M–$50M range positions Avrio Pharmacy between smaller independents and large chains, suggesting growth plays around scope expansion, pharmacy benefits partnerships, and contract opportunities with regional healthcare networks.

Tech-enabled trust Utilizing a tech stack including WordPress, Zoho, and Microsoft 365 alongside security and analytics tools signals readiness for partner integrations, marketing automation, and data-driven outreach to clinics and pet care providers.